Dr. Flamm is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St
Galter 17200
Chicago, IL 60611Phone+1 312-695-4837Fax+1 312-695-5998
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Gastroenterology, 1992 - 1996- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
IL State Medical License 1996 - 2026
IN State Medical License 2007 - 2025
FL State Medical License 2014 - 2019- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis Start of enrollment: 2007 Dec 01
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
- Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2014 Dec 09
Publications & Presentations
PubMed
- 630 citationsLedipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis
Gastroenterology. 2015-09-01 - 151 citationsInstitutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experienceRiad Salem, Ahmed Gabr, Ahsun Riaz, R. Mora, R. Ali
Hepatology. 2018-10-01 - 30 citationsRifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrenceSteven L. Flamm
Therapeutic Advances in Gastroenterology. 2011-03-18
Other
- Rifaximin Has the Potential to Prevent Complications of CirrhosisSteven Flamm, MD, Therapeutic Advances in Gastroenterology
https://www.doximity.com/articles/c793f763-2724-412e-bc64-709fadd2e091
UpToDate, Wolters Kluwer Health - 2010-09-07 - Rifaximin Has the Potential to Prevent Complications of CirrhosisSteven Flamm, MD, Therapeutic Advances in Gastroenterology
https://www.doximity.com/articles/c793f763-2724-412e-bc64-709fadd2e091
UpToDate, Wolters Kluwer Health - 2013-01-23 - Rifaximin Has the Potential to Prevent Complications of CirrhosisSteven Flamm, MD, Therapeutic Advances in Gastroenterology
https://www.doximity.com/articles/c793f763-2724-412e-bc64-709fadd2e091
UpToDate, Wolters Kluwer Health - 2012-09-17 - Join now to see all
Authored Content
- Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic EncephalopathyOctober 2018
Press Mentions
Singer Vicente Fernández Refused Transplant, Feared Donor a 'Homosexual or an Addict'May 16th, 2019
Hepatology News Tonight: Managing Complications of CirrhosisMarch 12th, 2019
Gastric Acid Drugs Not Found to Inhibit Efficacy of Hepatitis C TreatmentMarch 1st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
